This application generally relates to medical devices. More particularly, this application relates to stents having particular structural features.
The embodiments disclosed herein will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. These drawings depict only typical embodiments, which will be described with additional specificity and detail through use of the accompanying drawings in which:
Stents are disclosed herein. In some embodiments, the stents described herein comprise a tubular body having an interior dimension and comprising a midbody that extends to a first end and also extends to an opposing second end, where the midbody includes a thread arranged helically along at least a portion of its length. The thread can exhibit various shapes and/or dimensions selected to enhance particular aspects of performance when the stent is placed in an anatomical structure of a patient. Though stents may be described herein with reference to placement in the esophagus, this should be understood as one exemplary use. Stents in accordance with the present disclosure can be used in a number of placements, including but not limited to, gastrointestinal, colonic, biliary, pulmonary, vascular, pancreatic, and ureteral placements.
Embodiments may be understood by reference to the drawings, wherein like parts are designated by like numerals throughout. It will be readily understood by one of ordinary skill in the art having the benefit of this disclosure that the components of the embodiments, as generally described and illustrated in the figures herein, could be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of various embodiments, as represented in the figures, is not intended to limit the scope of the disclosure, but is merely representative of various embodiments. While the various aspects of the embodiments are presented in drawings, the drawings are not necessarily drawn to scale unless specifically indicated.
It will be appreciated that various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure. Many of these features may be used alone and/or in combination with one another.
The phrase “coupled to” refers to any form of interaction between two or more entities, including mechanical, electrical, magnetic, electromagnetic, fluid, and thermal interaction. Two components may be coupled to each other even though they are not in direct contact with each other. For example, two components may be coupled to each other through an intermediate component.
The directional terms “distal” and “proximal” are given their ordinary meaning in the art. That is, the distal end of a medical device means the end of the device furthest from the practitioner during use. The proximal end refers to the opposite end, or the end nearest the practitioner during use. As applied to a stent deployed within an esophagus, the proximal end of the stent refers to the end closest to the patient's head, and the distal end of the stent refers to the opposite end, the end closer to the patient's stomach.
As illustrated in
In another aspect, the inclusion of helical threads 110 may also aid in fluid flow through stented regions. For example, spiral laminar flow is a predominant type of arterial flow and is commonly seen in narrowing passages in the circulatory system. While not bound by any particular theory, the helical arrangement of the threads 110 can facilitate or enhance such flow in certain anatomical structures.
In other aspects, the helical thread 110 can enhance the mechanical properties of the stent 100. In one aspect, the helical thread 110 increases the axial and radial strength of the stent 100. This can be realized to a greater degree as stent 100 length increases, as compared to conventional unthreaded stents in which radial and axial strength decrease more drastically with increasing length. In another aspect, the helical thread 110 can decrease the stent's 100 resistance to lateral flexion, i.e., its bending force. Stated differently, the turns of the helical thread 110 provide flexion points that allow the stent 100 to bend more easily. The helical thread also enables the stent body to remain more open when placed in narrowing and tortuous anatomy, resisting collapsing/infolding. This can make the stent 100 more suited for navigating small and/or tortuous anatomy while keeping the lumen open and exerting less pressure on said anatomy.
In various embodiments, the stent 100 may comprise any suitable material known in the art, including metals, alloys thereof, and polymers. In some embodiments, the material may be a memory alloy, including but not limited to an alloy of nickel and titanium commonly known as Nitinol. In one example, biliary stents are made using “DFT wire” (drawn filled tubing) which consists of a Nitinol outer sheath and a core containing platinum to give fluoroscopic visibility. Other metals include magnesium, zinc, and iron. In some embodiments, the stent 100 can comprise a biodegradable material.
In some embodiments the stent 100 can comprise a grid or mesh structure. As illustrated in
In some embodiments, the braid pattern of the midbody (and/or of the entire stent) is a one-wire, two-over, two-under braid pattern (referred to as a “one over two” pattern), which means that a single strand passes over two strands (or two different portions of itself, such as in a single wire braid design) and then under two other strands (or yet two other portions of itself, such as in a single wire braid design). Alternative braid patterns may be used as well, such as a one-wire, one-over, one-under braid pattern (referred to as a “one over one” pattern). Other possible braid patterns include the diamond two-wire, one-over, one-under braid pattern and the diamond two-over, two-under braid pattern. Two strands can also be ‘hooked,’ or linked, together at their crossing point rather than passing over/under one another uninterrupted.
In some embodiments, the braid pattern may lead to differing cell requirements over the length of the stent 100, where a cell refers to the design created by the braid pattern. Thus, depending on stent length and braid pattern, the braid designs may result in fractional and non-fractional cell counts. For example, a stent 100 may be designed with a non-fractional cell count, in which a full braid pattern is completed on each end of the stent 100 and/or the stent 100 comprises only full braid patterns along the length of the stent 100. Non-fractional cell counts refer to a whole cell count. For example, a stent 100 with a non-fractional cell count may have, 20, 30, 40, 50, or more full cell counts, or full braid patterns along its length. Fractional cell counts refer to fractional cell count numbers, 20.5, 30.5, 40.5, 50.5 or more, meaning the stent 100 has a whole number of full cell counts in addition to a partial cell (or braid pattern) along the length of the stent 100. In some embodiments, the braid pattern may be one over one and may have a fractional or non-fractional cell count. In some embodiments, the braid pattern may be one over two and may have a fractional or non-fractional cell count.
As shown in
The pitch (i.e., axial distance between intersecting strands) also impacts the compressibility and stiffness of the braided or woven wires 114. In an aspect, a decrease in pitch, i.e. tighter pitch, may correlate with an increase in migration resistance of the stent 100. The pitch is related to the number of strands woven or braided together and the braid angle α, and therefore can vary over different geometries.
The braided or woven wires 114 may be braided or woven in a given pattern in accordance with an appropriate braid design, such as a closed-loop braid design, a single wire woven design, an endless braid design, or the like. In some embodiments, the wire 114 is braided in a closed-loop braid design in which multiple strands are interlaced in a first direction (e.g., a distal direction) and then turn and are interlaced back in an opposite second direction (e.g., back in the proximal direction). In still other embodiments, the stent 100 may have an endless braid design in which multiple strands are interlaced. In some embodiments, the braid pattern can comprise hook stitches. In other embodiments, a “hook and cross” braid pattern is used in which the pattern includes both hook stitches and cross stitches. In some embodiments, the braid pattern is created using an axial braiding approach. In some embodiments, the braid pattern is created using a radial braiding approach. Radial braiding involves creating a fractional cell count along the length of the stent, either a non-fractional or a fractional cell count can be selected with axial braiding.
In various embodiments, the braided or woven wires 114 are braided or woven so as to create a series of loops at one or both ends of the stent 100. The arrangement of these loops can be selected to provide desired functionality, such as for threading through of a suture line (discussed further below). In some embodiments the end loops are substantially aligned in one plane at the stent opening. In other embodiments, some end loops may protrude further than others. In certain embodiments, the length of the end loops can alternate.
The braided or woven wires 114 may include varying numbers of strands, where the number used can depend in part upon the size of the stent 100 and the braid or weave pattern. In some embodiments, the stent 100 includes a wire count from 24 to 72 wires, or more particularly from 32 to 64 wires, or more particularly from 48 to 56 wires. In other embodiments, a biliary stent in accordance with the present disclosure has a wire count from 16 to 44 wires. Wire counts increase by a factor of 4 with 1-over-1 braid patterns and by a factor of 8 with 1-over-2 braid patterns.
When braided or woven in a closed-loop braid design, the braided or woven wires 114 may start and stop at various locations on the stent 100. In an aspect, it can be advantageous to design the braid so that such termination points occur on surfaces of a substantially flat/uniform cylindrical geometry.
In certain embodiments, the thickness of a strand of the braided or woven wires 114 may be about 102 μm to about 381 μm, or more particularly from 140 μm to about 254 μm. In other embodiments, the thickness may be about 165 μm to about 178 μm. Generally speaking, smaller wires may be used with smaller diameter stents and larger diameter wires may be used with larger diameter stents. Also, while smaller diameter wires can be used for stents designed for “through the scope” placement, stents designed for “over the wire” placement can include wires having significantly larger diameters. Radiopaque markers and/or coils can also be incorporated into the stent 100 as desired.
In certain embodiments, the grid or mesh structure can be formed from a tube of a suitable material where the pattern is created by cutting material from the tube using a laser. In the case of a stent made from polymeric materials, the stent could be fabricated using 3D printing.
In some embodiments, as illustrated in
The cover 118 may be elastomeric, polymeric, or comprised of any other material suited/approved for use in the body. In some embodiments, the cover 118 may include polyurethane or silicone. In some embodiments, the cover may be applied such that it tends to ebb and flow into spaces between portions of the braided or woven wires 114, resulting in a “tire tread” like outer surface, rather than a smooth outer cover 118. This can allow tissue to lock into the pockets of the outer surface, thus potentially adding to the anti-migration properties in some embodiments. In some embodiments, the cover 118 is shaped such that the braided or woven wires 114 are uncovered in some regions of the stent 100, which can allow tissue to grow into these spaces to help secure the stent 100 in place. In some embodiments, the cover 118 can comprise two or more layers of material.
In addition, the stent 100 can include a suture 120 arranged about the proximal and/or distal ends of the stent 100. In some embodiments, the suture 120 can be woven through end loops formed at the end of the stent 100. The suture 120 can be configured to aid with loading of the stent 100 into a catheter or other delivery device and can also facilitate removal of the stent 100 from the body of a subject. The suture 120 may be woven in such a way that pulling it has a drawstring effect on the opening of the end of the stent 100. That is, pulling a portion of the suture 120 causes the suture 120 to draw the edges of the stent ends 104 and 106 and the cover 118 radially inward, elongating and narrowing the stent 100. In the case where the stent 100 is situated in a body lumen, this action facilitates removal by aiding disengagement of the stent 100 from the lumen wall.
In an aspect of the present disclosure, the features described herein provide for a wider array of stent dimensions. In some embodiments, the overall length of the stent may range from about 20 mm to about 250 mm, including ranging from about 20 mm to about 90 mm, or from about 60 mm to about 160 mm. In particular examples, the stent can have an overall length of about 100 mm and the midbody can have a length of about 50 mm, an overall length of about 120 mm and a midbody length of about 70 mm, or an overall length of about 150 mm and a midbody length of about 100 mm. The overall diameter can be from about 6 mm to about 45 mm. In particular embodiments, the overall diameter is about 6 mm to about 30 mm, or from about 14 mm to about 30 mm, or from about 30 mm to about 45 mm.
The helical thread can have a cross-sectional shape, which may be selected with a view to enhancing migration resistance in a particular anatomical structure and/or based on consideration of the materials and method used to fabricate the stent. In some embodiments, the helical thread can have a generally circular cross-sectional profile—i.e., the shape of the thread's profile defines at least part of a circle.
In some embodiments, the helical thread can have a cross-sectional profile with a generally elliptical geometry.
In various embodiments, the helical thread has a generally triangular cross-sectional profile. In some embodiments, an example of which is shown in
In some embodiments, the helical thread has a buttress-shaped cross-sectional profile, one example embodiment of which is shown in
Without being bound by or limited to a particular theory, such a shape may enhance migration resistance, where the thrust face 550 of the thread exerts force against the surrounding tissue to resist movement of the stent 500 in a particular direction, while the bracing face 552 performs a bracing function to strengthen and support the thrust face 550. Accordingly, in some embodiments, the helical thread 510 can be shaped such that the thrust face 550 faces the end of the stent 500 oriented in the direction in which migration is least desirable. For example, the thrust face 550 can face the distal end of a stent for use in an application (e.g., stenting of the esophagus) in which migration in the distal direction is more common.
The cross-sectional profile shapes described above are not intended to be exhaustive, and it is contemplated that stents in accordance with the present disclosure may include threads having other cross-sectional shapes as well as combinations of the foregoing. With respect to the various cross-sectional profile shapes, the height and breadth of the helical thread in absolute terms may depend to a degree on the overall dimensions of the stent, and the relationship between the height and breadth is determined in part by the profile geometry. For example, in some embodiments a stent (e.g. an esophageal stent) comprises a helical thread with a profile based on a circle having a diameter of from about 1 mm to about 10 mm, such that the maximum height of the helical thread is from about 0.5 mm to about 5 mm and the maximum width of the helical thread is from about 1 mm to about 10 mm. Some embodiments of a stent (e.g. an esophageal stent) can comprise a helical thread with a profile based on an oval having major diameter from about 1 mm to about 10 mm, such that the maximum height of the helical thread is from about 0.5 mm to about 5 mm and maximum width is from about 0.5 mm to 10 mm.
In various embodiments, a stent can comprise a helical thread having a plurality of thread heights. In some embodiments, the height of the thread can vary along a length of the stent, e.g., generally increasing or generally decreasing in height from one end to the other or varying in heights from one end to the other. In another example, the stent comprises two or more such helical threads or regions thereof exhibiting increasing height, decreasing height, or a combination thereof.
A particular aspect of the various embodiments discussed herein is the spacing between adjacent turns of the helical thread. The thread spacing (also termed “pitch”) can be selected with a view to providing desired benefits and performance in particular stenting applications. In one aspect, as discussed above, the helical thread contributes to the axial strength of the stent. The degree to which the thread enhances axial strength is affected by the thread spacing, where decreased thread spacing increases axial strength. One manifestation of increased axial strength is increased resistance to stretching. Accordingly, in various embodiments the thread spacing is selected so as to be small enough to provide a useful degree of axial strength, while not being so small as to produce a degree of spring-like behavior that may increase migration of the stent. For example, some decrease in spacing can increase the self-expansion force, i.e., hoop force of the stent, which contributes to migration resistance by enhancing contact between the outer surface of the stent and surrounding tissue. In a related aspect, as each turn of the helical thread provides a contact surface that interacts with surrounding tissue, such a decrease in thread spacing will result in the stent exhibiting a higher thread density as well as more total turns of the thread, thereby increasing migration resistance. In another aspect of the foregoing, decreasing thread spacing beyond a certain point decreases the spacing and structure between the thread features, which may result in the loss or reversal of such effects, i.e., decreased hoop force and decreased flexibility resulting in decreased migration resistance. These respective spacing ranges may depend upon various design parameters including, but not limited to, the type of stent, the dimensions of the stent, wire count, and wire size.
In some embodiments, a stent can comprise a helical thread having a constant thread spacing. In other embodiments, a helical thread can include a plurality of thread spacings.
The actual spacing between turns of the helical thread in standard units of length can depend on the overall dimensions of the stent. In another aspect, thread spacing may be selected in view of the methods and materials used to fabricate the stent. For example, in stents constructed of woven or braided wire, thread spacing may be selected based on elements of the pattern. In a particular example, a thread spacing is selected so that the interthread space is at least from 1 to 7 cells in width, or more particularly from 2 to 5 cells in width. In certain embodiments, a stent can include interthread spaces from about 2 mm to about 20 mm, or more particularly from about 4 mm to about 15 mm. In more particular embodiments, the stent is constructed of braided wire and the interthread spaces are at least 2 cells in width.
In some embodiments, a stent may feature multiple regions in which the presence or absence of helical thread and/or the spacing of the helical thread is selected to accommodate the structure and function of the stent. For example, as discussed above, a stent may employ tighter spacing at regions along the stent where greater migration resistance and/or axial strength is desired, while exhibiting looser spacing (or alternatively, no thread at all) in other regions. In another example, increased thread spacing or absent threading may be employed in a region of a stent to accommodate design considerations associated with a specialized structure of that region (e.g., the presence of an anti-reflux valve in an esophageal stent so equipped).
In other embodiments, decreased thread pitch can be increased through the inclusion of more than one helical thread on a stent. For example, a stent can include two, three, or four helical threads, each of which starts at a different point around the circumference of the stent, either originating at the same or different positions along the axis of the stent. In a particular example, a stent can have a double start helical thread in which the two threads are positioned 180 degrees apart and start at the same position along the axis of the stent.
Another aspect is the availability of the stent body or designated portions thereof, e.g., the interthread spaces or the thread itself, to include additional features, including but not limited to anti-migration features, adhesives, and the like. In some embodiments, as illustrated in
Similarly, in some embodiments a helical thread may be included in areas of the stent in addition to the midbody. In some embodiments, a helical thread can be employed on one or both ends of a stent, either in addition to helical threads on the stent midbody or exclusively, i.e., without thread features on the stent midbody. As illustrated in
Stents with helical threads in accordance with the present disclosure can also include other structural features.
In an aspect of the foregoing, the flanges may contribute to migration resistance by interacting with the surfaces of a lumen in a subject's body. In some embodiments, additional anti-migration benefits may be realized by increasing the number of flanges to provide additional surfaces for contact between the stent and adjacent tissue.
The sleeve can serve to confer a feature or property on a portion of a stent that may be absent elsewhere on the stent. For example, an inner cylindrical sleeve can be used to anchor a unique feature, e.g. an anti-reflux valve. In another example, an outer threaded sleeve can be disposed over a portion of the length of the stent to provide added migration resistance and/or axial strength to that specific portion. This can be of benefit where the lumen in which the stent is placed has varying anatomical characteristics. Accordingly, in some embodiments, the sleeve is fixedly secured to the stent so that there is little to no movement of one component relative to the other. In other embodiments, the sleeve is configured to allow movement of the stent relative to the sleeve. In certain embodiments, the sleeve and/or the stent are configured so that such movement is limited or to otherwise maintain a connection between the sleeve and the stent. In certain embodiments, one or both ends of the stent can include flanges or other structures that limit the relative movement between the stent and the sleeve.
In some embodiments, the stent and the sleeve can be constructed from or include different materials. For example, in some embodiments, the stent can include a cover to provide the benefits discussed above, while at least a portion of the sleeve does not include a cover. An aspect of such an arrangement is that benefits of a cover can be realized, e.g., smoother flow of matter through the interior space of the stent and/or greater ease of removal, while also realizing benefits of uncovered material, e.g., enhanced migration resistance through tissue ingrowth.
As discussed above, structural considerations can influence the placement method (e.g., “through-the-scope” or “over the wire”) for which stents described herein are suited. Stents designed for “over the wire” placement can include wires having significantly larger diameters. In some embodiments, the two-layer assembly is designed for use in “over the wire” placement based on the amount of material involved in their construction.
Any methods disclosed herein comprise one or more steps or actions for performing the described method. The method steps and/or actions may be interchanged with one another. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order and/or use of specific steps and/or actions may be modified.
References to approximations are made throughout this specification, such as by use of the terms “substantially” and “about.” For each such reference, it is to be understood that, in some embodiments, the value, feature, or characteristic may be specified without approximation. For example, where qualifiers such as “about” and “substantially” are used, these terms include within their scope the qualified words in the absence of their qualifiers. For example, where the term “substantially perpendicular” is recited with respect to a feature, it is understood that in further embodiments, the feature can have a precisely perpendicular configuration. All ranges also include both endpoints.
Similarly, in the above description of embodiments, various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure. This method of disclosure, however, is not to be interpreted as reflecting an intention that any claim require more features than those expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment.
The claims following this written disclosure are hereby expressly incorporated into the present written disclosure, with each claim standing on its own as a separate embodiment. This disclosure includes all permutations of the independent claims with their dependent claims. Moreover, additional embodiments capable of derivation from the independent and dependent claims that follow are also expressly incorporated into the present written description.
Without further elaboration, it is believed that one skilled in the art can use the preceding description to utilize the invention to its fullest extent. The claims and embodiments disclosed herein are to be construed as merely illustrative and exemplary, and not a limitation of the scope of the present disclosure in any way. It will be apparent to those having ordinary skill in the art, with the aid of the present disclosure, that changes may be made to the details of the above-described embodiments without departing from the underlying principles of the disclosure herein. In other words, various modifications and improvements of the embodiments specifically disclosed in the description above are within the scope of the appended claims. Moreover, the order of the steps or actions of the methods disclosed herein may be changed by those skilled in the art without departing from the scope of the present disclosure. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order or use of specific steps or actions may be modified. The scope of the invention is therefore defined by the following claims and their equivalents.
This application claims priority to U.S. Provisional Patent Application No. 63/105,747, filed on Oct. 26, 2020, entitled “ESOPHAGEAL STENTS WITH HELICAL THREAD,” which is hereby incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4913141 | Hillstead | Apr 1990 | A |
5201757 | Heyn et al. | Apr 1993 | A |
5413575 | Haenggi | May 1995 | A |
5534007 | Germain et al. | Jul 1996 | A |
5591172 | Bachmann et al. | Jan 1997 | A |
5591196 | Marin et al. | Jan 1997 | A |
5603698 | Roberts et al. | Feb 1997 | A |
5645559 | Hachtman et al. | Jul 1997 | A |
5733325 | Robinson et al. | Mar 1998 | A |
5755769 | Richard et al. | May 1998 | A |
5759186 | Bachmann et al. | Jun 1998 | A |
5824041 | Lenker et al. | Oct 1998 | A |
5868755 | Kanner et al. | Feb 1999 | A |
5876448 | Thompson et al. | Mar 1999 | A |
5916147 | Boury | Jun 1999 | A |
5944727 | Ahari et al. | Aug 1999 | A |
5968052 | Sullivan, III et al. | Oct 1999 | A |
6015429 | Lau et al. | Jan 2000 | A |
6093194 | Mikus et al. | Jul 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6143021 | Staehle | Nov 2000 | A |
6146415 | Fitz | Nov 2000 | A |
6162231 | Mikus et al. | Dec 2000 | A |
6241757 | An et al. | Jun 2001 | B1 |
6270524 | Kim | Aug 2001 | B1 |
6283992 | Hankh et al. | Sep 2001 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6383211 | Staehle | May 2002 | B1 |
6391051 | Sullivan, III et al. | May 2002 | B2 |
6413269 | Bui et al. | Jul 2002 | B1 |
6416545 | Mikus et al. | Jul 2002 | B1 |
6428566 | Holt | Aug 2002 | B1 |
6443980 | Wang et al. | Sep 2002 | B1 |
6447531 | Amplatz | Sep 2002 | B1 |
6514261 | Randall et al. | Feb 2003 | B1 |
6520983 | Colgan et al. | Feb 2003 | B1 |
6530933 | Yeung et al. | Mar 2003 | B1 |
6599296 | Gillick et al. | Jul 2003 | B1 |
6599308 | Amplatz | Jul 2003 | B2 |
6613079 | Wolinsky et al. | Sep 2003 | B1 |
6616675 | Evard et al. | Sep 2003 | B1 |
6629981 | Dennis et al. | Oct 2003 | B2 |
6645143 | Vantassel et al. | Nov 2003 | B2 |
6669719 | Wallace et al. | Dec 2003 | B2 |
6726712 | Raeder-Devens et al. | Apr 2004 | B1 |
6746480 | Scholz et al. | Jun 2004 | B2 |
6770101 | Desmond, III et al. | Aug 2004 | B2 |
6776791 | Jody et al. | Aug 2004 | B1 |
6821295 | Farrar | Nov 2004 | B1 |
6866669 | Buzzard et al. | Mar 2005 | B2 |
6893413 | Martin | May 2005 | B2 |
6926732 | Derus et al. | Aug 2005 | B2 |
6955685 | Escamilla et al. | Oct 2005 | B2 |
7004966 | Edwin et al. | Feb 2006 | B2 |
7083640 | Lombardi et al. | Aug 2006 | B2 |
7309350 | Landreville et al. | Dec 2007 | B2 |
7309351 | Escamilla et al. | Dec 2007 | B2 |
7335224 | Ohlenschaeger | Feb 2008 | B2 |
7393357 | Stelter et al. | Jul 2008 | B2 |
7473271 | Gunderson | Jan 2009 | B2 |
7591848 | Allen | Sep 2009 | B2 |
7637942 | Mangiardi et al. | Dec 2009 | B2 |
7731654 | Mangiardi et al. | Jun 2010 | B2 |
7959671 | Mangiardi et al. | Jun 2011 | B2 |
8012194 | Edwin et al. | Sep 2011 | B2 |
8206436 | Mangiardi et al. | Jun 2012 | B2 |
8262719 | Erickson et al. | Sep 2012 | B2 |
8357193 | Phan et al. | Jan 2013 | B2 |
8414635 | Hyodoh et al. | Apr 2013 | B2 |
8425539 | Binmoeller et al. | Apr 2013 | B2 |
8439934 | Satasiya et al. | May 2013 | B2 |
8454632 | Binmoeller et al. | Jun 2013 | B2 |
8518099 | Chanduszko et al. | Aug 2013 | B2 |
8524132 | Von Oepen et al. | Sep 2013 | B2 |
8535366 | Mangiardi et al. | Sep 2013 | B2 |
8652099 | Fierens et al. | Feb 2014 | B2 |
8677874 | Lilburn et al. | Mar 2014 | B2 |
8696611 | Yaacov et al. | Apr 2014 | B2 |
8715334 | Clerc et al. | May 2014 | B2 |
8834558 | Nissl | Sep 2014 | B2 |
8906081 | Cully et al. | Dec 2014 | B2 |
8926683 | Darla et al. | Jan 2015 | B2 |
9107741 | Bui | Aug 2015 | B2 |
9155643 | Clerc et al. | Oct 2015 | B2 |
9192496 | Robinson | Nov 2015 | B2 |
9259336 | Schaeffer et al. | Feb 2016 | B2 |
9284637 | Boyle et al. | Mar 2016 | B2 |
9381041 | Brown et al. | Jul 2016 | B2 |
10285834 | Cindrich et al. | May 2019 | B2 |
20010037141 | Yee et al. | Nov 2001 | A1 |
20020068037 | Platzet et al. | Jun 2002 | A1 |
20020138095 | Mazzocchi et al. | Sep 2002 | A1 |
20020151967 | Mikus et al. | Oct 2002 | A1 |
20020183827 | Derus et al. | Dec 2002 | A1 |
20020193749 | Olovson | Dec 2002 | A1 |
20030023268 | Lizardi | Jan 2003 | A1 |
20030028236 | Gillick | Feb 2003 | A1 |
20030050686 | Raeder-Devens et al. | Mar 2003 | A1 |
20030135265 | Stinson | Jul 2003 | A1 |
20030135268 | Desai | Jul 2003 | A1 |
20030144671 | Brooks et al. | Jul 2003 | A1 |
20030167060 | Buzzard et al. | Sep 2003 | A1 |
20040030381 | Shu | Feb 2004 | A1 |
20040098077 | Gianotti | May 2004 | A1 |
20040127973 | Mangiardi et al. | Jul 2004 | A1 |
20040181239 | Dorn et al. | Sep 2004 | A1 |
20040193243 | Mangiardi et al. | Sep 2004 | A1 |
20040267281 | Harari et al. | Dec 2004 | A1 |
20050027345 | Horan et al. | Feb 2005 | A1 |
20050038495 | Greenan | Feb 2005 | A1 |
20050090887 | Pryor | Apr 2005 | A1 |
20050125050 | Carter et al. | Jun 2005 | A1 |
20050149160 | McFerran | Jul 2005 | A1 |
20050182475 | Jen et al. | Aug 2005 | A1 |
20050278010 | Richardson | Dec 2005 | A1 |
20050283179 | Lentz | Dec 2005 | A1 |
20060020321 | Parker | Jan 2006 | A1 |
20060155368 | Shin | Jul 2006 | A1 |
20060184224 | Angel | Aug 2006 | A1 |
20060258972 | Mangiardi et al. | Nov 2006 | A1 |
20060259113 | Nissl | Nov 2006 | A1 |
20070005122 | Inoue | Jan 2007 | A1 |
20070043421 | Mangiardi et al. | Feb 2007 | A1 |
20070100421 | Griffin | May 2007 | A1 |
20070135904 | Eidenschink et al. | Jun 2007 | A1 |
20070156225 | George et al. | Jul 2007 | A1 |
20070179590 | Lu et al. | Aug 2007 | A1 |
20070208350 | Gunderson | Sep 2007 | A1 |
20070250150 | Pal et al. | Oct 2007 | A1 |
20070270932 | Headley et al. | Nov 2007 | A1 |
20080114443 | Mitchell et al. | May 2008 | A1 |
20080140178 | Rasmussen et al. | Jun 2008 | A1 |
20080228256 | Erickson | Sep 2008 | A1 |
20080288042 | Purdy et al. | Nov 2008 | A1 |
20090099636 | Chanduszko et al. | Apr 2009 | A1 |
20090099647 | Glimsdale et al. | Apr 2009 | A1 |
20090118740 | Mangiardi et al. | May 2009 | A1 |
20090157158 | Ondracek | Jun 2009 | A1 |
20090171427 | Melsheimer et al. | Jul 2009 | A1 |
20090171433 | Melsheimer | Jul 2009 | A1 |
20090187240 | Clerc | Jul 2009 | A1 |
20090192518 | Golden et al. | Jul 2009 | A1 |
20090292262 | Adams et al. | Nov 2009 | A1 |
20100023032 | Granja et al. | Jan 2010 | A1 |
20100023132 | Imran | Jan 2010 | A1 |
20100030256 | Dubrul et al. | Feb 2010 | A1 |
20100030321 | Mach | Feb 2010 | A1 |
20100049295 | Satasiya et al. | Feb 2010 | A1 |
20100057145 | Bhatnagar et al. | Mar 2010 | A1 |
20100057185 | Melsheimer et al. | Mar 2010 | A1 |
20100070016 | Dorn | Mar 2010 | A1 |
20100145431 | Wu et al. | Jun 2010 | A1 |
20100252470 | Ryan et al. | Oct 2010 | A1 |
20110004290 | Bales, Jr. et al. | Jan 2011 | A1 |
20110015616 | Straubinger et al. | Jan 2011 | A1 |
20110082464 | Douk et al. | Apr 2011 | A1 |
20110137396 | Dorn et al. | Jun 2011 | A1 |
20110137400 | Dorn et al. | Jun 2011 | A1 |
20110190862 | Bashiri et al. | Aug 2011 | A1 |
20110208296 | Duffy et al. | Aug 2011 | A1 |
20110264191 | Rothstein | Oct 2011 | A1 |
20110288482 | Farrell et al. | Nov 2011 | A1 |
20110307070 | Clerc et al. | Dec 2011 | A1 |
20110319980 | Ryan | Dec 2011 | A1 |
20120046729 | Von Oepen et al. | Feb 2012 | A1 |
20120095567 | Weisman et al. | Apr 2012 | A1 |
20120136426 | Phan et al. | May 2012 | A1 |
20120290066 | Nabulsi et al. | Nov 2012 | A1 |
20120296257 | Van Dan et al. | Nov 2012 | A1 |
20120303109 | Okuma | Nov 2012 | A1 |
20120303112 | Armstrong et al. | Nov 2012 | A1 |
20120310320 | Gill et al. | Dec 2012 | A1 |
20130018215 | Snider et al. | Jan 2013 | A1 |
20130103163 | Krimsky et al. | Apr 2013 | A1 |
20130110221 | Campbell et al. | May 2013 | A1 |
20130116770 | Robinson | May 2013 | A1 |
20130116771 | Robinson | May 2013 | A1 |
20130116772 | Robinson et al. | May 2013 | A1 |
20130158673 | Toomey | Jun 2013 | A1 |
20130184833 | Ryan et al. | Jul 2013 | A1 |
20130197623 | McHugo | Aug 2013 | A1 |
20130231689 | Binmoeller et al. | Sep 2013 | A1 |
20130253546 | Sander et al. | Sep 2013 | A1 |
20130274870 | Lombardi et al. | Oct 2013 | A1 |
20130310833 | Brown et al. | Nov 2013 | A1 |
20140074065 | Muni et al. | Mar 2014 | A1 |
20140074219 | Hingston et al. | Mar 2014 | A1 |
20140171863 | Blacker | Jun 2014 | A1 |
20140236064 | Binmoeller et al. | Aug 2014 | A1 |
20140243992 | Walsh et al. | Aug 2014 | A1 |
20140277573 | Gill et al. | Sep 2014 | A1 |
20140288636 | Headley, Jr. et al. | Sep 2014 | A1 |
20140303709 | Dwork | Oct 2014 | A1 |
20140330305 | Rood et al. | Nov 2014 | A1 |
20140350694 | Behan | Nov 2014 | A1 |
20140364959 | Attar et al. | Dec 2014 | A1 |
20150066128 | Losordo et al. | Mar 2015 | A1 |
20150100133 | Xie et al. | Apr 2015 | A1 |
20150112377 | Arnone et al. | Apr 2015 | A1 |
20150173919 | Baldwin | Jun 2015 | A1 |
20150230955 | Farag Eells et al. | Aug 2015 | A1 |
20150313595 | Houshton et al. | Nov 2015 | A1 |
20150313599 | Johnson et al. | Nov 2015 | A1 |
20160081823 | Majercak | Mar 2016 | A1 |
20160081832 | Hingston et al. | Mar 2016 | A1 |
20160242846 | Brown et al. | Aug 2016 | A1 |
20160256306 | Cindrich et al. | Sep 2016 | A1 |
20170014133 | Han et al. | Jan 2017 | A1 |
20170035424 | Binmoeller et al. | Feb 2017 | A1 |
20170035426 | Phan et al. | Feb 2017 | A1 |
20170035427 | Sander et al. | Feb 2017 | A1 |
20170035428 | Binmoeller et al. | Feb 2017 | A1 |
20170354404 | Chu | Dec 2017 | A1 |
20180185183 | Christakis et al. | Jul 2018 | A1 |
20180193175 | Bluecher | Jul 2018 | A1 |
20180263797 | Eller et al. | Sep 2018 | A1 |
20180303594 | Eller et al. | Oct 2018 | A1 |
20190099589 | Walsh et al. | Apr 2019 | A1 |
20190254804 | Folan et al. | Aug 2019 | A1 |
20200375768 | Eller et al. | Dec 2020 | A1 |
20210121306 | Henchie et al. | Apr 2021 | A1 |
20210145563 | Folan | May 2021 | A1 |
20210161692 | Mower et al. | Jun 2021 | A1 |
20220023026 | Eller et al. | Jan 2022 | A1 |
20230381000 | Eller et al. | Nov 2023 | A1 |
Number | Date | Country |
---|---|---|
210185778 | Mar 2020 | CN |
4323866 | Jan 1994 | DE |
102005051469 | Apr 2007 | DE |
0364420 | Apr 1990 | EP |
0408245 | Jan 1991 | EP |
0872220 | Oct 1998 | EP |
1637092 | Mar 2006 | EP |
2522316 | Nov 2012 | EP |
199631174 | Oct 1996 | WO |
200018330 | Apr 2000 | WO |
2000078246 | Dec 2000 | WO |
2002056798 | Jul 2002 | WO |
2002087470 | Nov 2002 | WO |
2003090644 | Nov 2003 | WO |
2004030571 | Apr 2004 | WO |
2005070095 | Aug 2005 | WO |
2008042266 | Apr 2008 | WO |
2010130297 | Nov 2010 | WO |
2013045262 | Apr 2013 | WO |
2013052528 | Apr 2013 | WO |
2013066883 | Oct 2013 | WO |
2015184154 | Dec 2015 | WO |
2019099080 | May 2019 | WO |
2020146261 | Jul 2020 | WO |
Entry |
---|
International Search Report and Written Opinion dated Jan. 9, 2018 for PCT/US2017/054000. |
Office Action dated Jan. 3, 2014 for U.S. Appl. No. 11/432,964. |
Office Action dated Jul. 25, 2013 for U.S. Appl. No. 11/432,964. |
Office Action dated Aug. 13, 2012 for U.S. Appl. No. 10/585,430. |
Office Action dated Sep. 19, 2018 for U.S. Appl. No. 15/061,107. |
Office Action dated Oct. 7, 2015 for U.S. Appl. No. 13/664,234. |
Office Action dated Oct. 16, 2015 for U.S. Appl. No. 13/664,267. |
Office Action dated Oct. 16, 2017 for U.S. Appl. No. 15/061,107. |
Office Action dated Nov. 9, 2010 for U.S. Appl. No. 10/585,430. |
Office Action dated Nov. 14, 2012 for U.S. Appl. No. 12/535,980. |
Office Action dated Nov. 14, 2018 for U.S. Appl. No. 15/263,741. |
Office Action dated Nov. 19, 2015 for U.S. Appl. No. 13/664,137. |
Office Action dated Nov. 30, 2016 for U.S. Appl. No. 13/664,137. |
Office Action dated Dec. 2, 2019 for U.S. Appl. No. 15/718,419. |
Office Action dated Dec. 7, 2009 for U.S. Appl. No. 11/432,964. |
Office Action dated Dec. 8, 2009 for U.S. Appl. No. 10/585,430. |
Office Action dated Dec. 22, 2020 for U.S. Appl. No. 15/921,220. |
Cheon, et al.,Clinical Feasibility of a New Through-The-Scope Fully Covered Esophageal Self-Expandable Metallic Stent: An In Vivo Animal Study, Digestive Endoscopy, vol. 26 No. 1 ,2014 ,32-36. |
Kawakami, et al.,Endoscopic Ultrasound-Guided Transluminal Drainage for Peripancreatic Fluid Collections: Where are we now?, Gut and Liver, vol. 8 No. 4 ,2014 ,341-355. |
Sen, et al.,Laplace's Equation for Convective Scalar Transport in Potential Flow, Proc. R. Soc. Lond. A 456, pp. 3041-3045 ,2000. |
Sizarov, et al.,Novel materials and Devices in the Transcatheter Creation of vascular Anastomosis—The Future Comes Slowly (Part 2), Archives of Cardiovascular Diseases, vol. 109 No. 4 ,2016 ,286-295. |
Weilert, et al.,Specially Designed Stents for Translumenal Drainage, Gastrointestinal Intervention, vol. 4 No. 1 ,2015 ,40-45. |
European Search Report dated Nov. 9, 2020 for EP18767753.9. |
International Search Report and Written Opinion dated Feb. 14, 2022 for PCT/US2021/056495. |
International Search Report and Written Opinion dated Nov. 9, 2021 for PCT/US2021/042833. |
Notice of Allowance dated Jul. 22, 2020 for U.S. Appl. No. 15/718,419. |
Office Action dated Apr. 15, 2022 for U.S. Appl. No. 15/921,220. |
Office Action dated Nov. 9, 2021 for U.S. Appl. No. 15/921,220. |
Office Action dated Nov. 25, 2022 for U.S. Appl. No. 16/994,260. |
European Examination Report dated Feb. 18, 2015 for EP09791142.4. |
European Examination Report dated Apr. 26, 2021 for EP11846358.7. |
European Search Report dated Mar. 19, 2021 for EP18768455.0. |
European Search Report dated Apr. 24, 2020 for EP17857414.1. |
European Search Report dated Dec. 15, 2020 for EP18768455.0. |
European Search dated Sep. 24, 2018 for EP16759580. |
International Preliminary Report dated May 15, 2014 for PCT/US2012/062603. |
International Publication and Search Report dated Jun. 14, 2012 for WO2012078794. |
International Publication and Search Report dated Feb. 25, 2012 for WO2010021836. |
International Search Report and Written Opinion dated Mar. 16, 2012 for PCT/US2011/063799. |
International Search Report and Written Opinion dated Mar. 29, 2013 for PCT/US2012/062603. |
International Search Report and Written Opinion dated Jun. 22, 2016 for PCT/US2016/020900. |
International Search Report and Written Opinion dated Jun. 29, 2018 for PCT/US2018/022340. |
International Search Report and Written Opinion dated Jun. 29, 2018 for PCT/US2018/022344. |
International Search Report and Written Opinion dated Aug. 2, 2018 for PCT/US2018/028107. |
International Search Report and Written Opinion dated Sep. 28, 2005 for PCT/US2005/000515. |
International Search Report and Written Opinion dated Oct. 29, 2009 for PCT/US2009/052691. |
International Search Report and Written Opinion dated Nov. 23, 2006 for PCT/US2006/018811. |
Notice of Allowance dated Jan. 14, 2015 for U.S. Appl. No. 11/432,964. |
Notice of Allowance dated Feb. 25, 2019 for U.S. Appl. No. 15/061,107. |
Notice of Allowance dated Mar. 6, 2013 for U.S. Appl. No. 12/535,980. |
Notice of Allowance dated Jun. 11, 2013 for U.S. Appl. No. 10/585,430. |
Notice of Allowance dated Jun. 22, 2016 for U.S. Appl. No. 13/664,267. |
Notice of Allowance dated Aug. 12, 2015 for U.S. Appl. No. 13/664,200. |
Notice of Allowance dated Sep. 6, 2018 for U.S. Appl. No. 29/597,873. |
Notice of Allowance dated Sep. 11, 2019 for U.S. Appl. No. 15/263,741. |
Notice of Allowance dated Sep. 23, 2016 for U.S. Appl. No. 13/664,234. |
Notice of Allowance dated Oct. 21, 2014 for U.S. Appl. No. 13/313,929. |
Office Action dated Jan. 22, 2013 for U.S. Appl. No. 10/585,430. |
Office Action dated Jan. 31, 2012 for U.S. Appl. No. 10/585,430. |
Office Action dated Feb. 5, 2020 for U.S. Appl. No. 15/921,172. |
Office Action dated Mar. 6, 2020 for U.S. Appl. No. 15/955,895. |
Office Action dated Mar. 16, 2015 for U.S. Appl. No. 13/664,234. |
Office Action dated Mar. 22, 2016 for U.S. Appl. No. 13/664,234. |
Office Action dated Mar. 24, 2015 for U.S. Appl. No. 13/664,267. |
Office Action dated Apr. 6, 2016 for U.S. Appl. No. 13/664,137. |
Office Action dated Apr. 7, 2020 for U.S. Appl. No. 15/955,895. |
Office Action dated Apr. 25, 2018 for U.S. Appl. No. 15/061,107. |
Office Action dated May 5, 2014 for U.S. Appl. No. 13/313,929. |
Office Action dated May 21, 2021 for U.S. Appl. No. 15/921,220. |
Office Action dated May 25, 2012 for U.S. Appl. No. 12/535,980. |
Office Action dated May 30, 2019 for U.S. Appl. No. 15/263,741. |
Office Action dated Jun. 7, 2011 for U.S. Appl. No. 10/585,430. |
Office Action dated Jul. 9, 2009 for U.S. Appl. No. 11/432,964. |
Notice of Allowance dated Mar. 15, 2023 for U.S. Appl. No. 16/994,260. |
International Publication and Search Report dated Aug. 4, 2005 for WO2005070095. |
Office Action dated Oct. 26, 2023 for U.S. Appl. No. 17/383,221. |
Number | Date | Country | |
---|---|---|---|
20220125608 A1 | Apr 2022 | US |
Number | Date | Country | |
---|---|---|---|
63105747 | Oct 2020 | US |